Meeting
2012 ASCO Annual Meeting
Estrogen receptor (ER), Ki-67, p27Kip1, and histologic grade as predictors of pathologic complete response (pCR) in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy (NAC) using fluorouracil, epirubicin, and cyclophosphamide (FEC), taxanes, and trastuzumab.
Authors
Sasagu Kurozumi
Saitama Cancer Center, Saitama, Japan
Sasagu Kurozumi , Kenichi Inoue , Hiroyuki Takei , Hiroshi Matsumoto , Takashi Yoshida , Yuji Hayashi , Jun Ninomiya , Kazuyuki Kubo , Shigenori E Nagai , Hanako Oba , Masafumi Kurosumi , Toshio Tabei , Jun Horiguchi , Izumi Takeyoshi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Citation
J Clin Oncol 30, 2012 (suppl; abstr 613)
DOI
10.1200/jco.2012.30.15_suppl.613
Abstract #
613
Poster Bd #
10H
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Pathologic complete response (pCR) rates after neoadjuvant pertuzumab (P) and trastuzumab (H) administered concomitantly with weekly paclitaxel (T) and 5-fluorouracil/epirubicin/cyclophosphamide (FEC) chemotherapy for clinical stage I-III HER2-positive breast cancer.
First Author: Julia Foldi
Poster
2022 ASCO Annual Meeting
Assessing response to neoadjuvant docetaxel and trastuzumab in Nigerian women with HER2-positive breast cancer (ARETTA).
First Author: Atara Isaiah Ntekim
Poster
2016 ASCO Annual Meeting
Tolerability and effectiveness of pertuzumab-containing neoadjuvant (NA) regimens vs. AC-TH for HER2-positive (+) localized breast cancer (BC).
First Author: Laura Spring
Poster
2015 ASCO Annual Meeting
Total pathologic complete response (tpCR) and event-free survival (EFS) with subcutaneous (SC) or intravenous (IV) trastuzumab in HER2-positive early breast cancer (EBC).
First Author: Christian Jackisch